Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals IncfiledCriticalAlnylam Pharmaceuticals Inc
Publication of AR117458A1publicationCriticalpatent/AR117458A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Agentes y composiciones de ácido ribonucleico de hebra doble (ARNihd) dirigidos al gen APP, métodos para inhibir la expresión de un gen APP y métodos de tratamiento de sujetos que padecen una enfermedad o trastorno asociado a APP, tal como una angiopatía amiloide cerebral (CAA) y el mal de Alzheimer familiar de inicio temprano (EOFAD o eFAD), usando dichos agentes y composiciones de ARNihd.Double-stranded ribonucleic acid (dRNA) agents and compositions targeting the APP gene, methods of inhibiting the expression of an APP gene, and methods of treating subjects suffering from an APP-associated disease or disorder, such as cerebral amyloid angiopathy (CAA). ) and early-onset familial Alzheimer's disease (EOFAD or eFAD), using such agents and dRNA compositions.
ARP190103781A2018-12-192019-12-19
COMPOSITIONS OF ARNi AGENTS FOR AMYLOID PRECURSOR PROTEIN (APP) AND THEIR METHODS OF USE
AR117458A1
(en)